Stockscreener 앱 받기
0.7184
1.52%
-0.0111
Skye Bioscience Inc 주식(SKYE)의 최신 뉴스
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Cuts Target Price to $6 - 富途牛牛
SKYE News | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience (SKYE) Surges 5% as Key Support Holds, Resistance in FocusPut Wall - newsline.com
SKYE Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Pipeline, Stock RisesEBITDA Margin Trends - newsline.com
SKYE Stock Chart | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience (SKYE) Holds Near Support Amid Modest GainsDividend ETF - newsline.com
Skye Bioscience, Inc. Amends Articles of Incorporation to Increase Authorized Shares – SEC 8-K Filing May 2026 - Minichart
Skye Bioscience Expands Authorized Shares After Shareholder Approval - TipRanks
Skye Bioscience (NASDAQ: SKYE) holders back major share authorization increase - Stock Titan
Skye Bioscience (SKYE) Tumbles 8.8% as Selling Pressure Intensifies, Support in SightFactor Rotation - The Legal Advocate
SKYE Stock Quote Price and Forecast - CNN
SKYE Q1 2026 Earnings: EPS Miss Masks Steady Pipeline ProgressEarnings Manipulation Risk - newsline.com
Skye Bioscience (SKYE) Edges Higher, Testing Resistance Near Key LevelsUpthrust Pattern - The Legal Advocate
Skye Bioscience (SKYE) Edges Higher Amid Renewed Buyer InterestNarrow Range Breakout - The Legal Advocate
Skye Bioscience (SKYE) Holds Above Support After Modest GainTrading Ideas - newsline.com
SKYE Q1 2026 Earnings: EPS Misses Estimates Amid No Revenue, Shares Edge HigherReturn On Assets - The Legal Advocate
Skye Bioscience (SKYE) Edges Higher as Support Holds, Testing Key Resistance at $0.88Volume Oscillator - The Legal Advocate
SKYE Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues DevelopmentEarnings Analysis - newsline.com
SKYE: All proposals passed, directors elected, and no stakeholder questions were raised - TradingView
SKYE Q1 2026 Earnings: EPS Slightly Below Estimates, Stock Surges 16% on Strategic ProgressMargin Guidance - The Legal Advocate
Skye Bioscience Rallies; Holiday Week Puts Focus on Tuesday - Bez Kabli
Skye Bioscience Surges 7.7%: Biotech Stock Tests Resistance at $0.81IV Percentile - newsline.com
Skye Bioscience gets approval to open second cohort in study By Investing.com - Investing.com Australia
Skye announces cohort review committee approved opening of cohort 2 based on favorable safety data from first four participants treated in cohort 1 - marketscreener.com
Skye Bioscience gets approval to open second cohort in study - Investing.com
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 - The Manila Times
Skye Announces Cohort Review Committee Approved Opening of - GlobeNewswire
Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87 - MSN
Skye Bioscience Faces Nasdaq Compliance Risk Over Equity - The Globe and Mail
[8-K] Skye Bioscience, Inc. Reports Material Event - Stock Titan
Nimacimab obesity trial progresses as Skye Bioscience initiates CBeyond study Part C - Traders Union
William Blair Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating - Moomoo
Skye Bioscience 4Q Loss/Shr 36c >SKYE - Moomoo
UPDATESkye Bioscience Reports First Quarter 2026 Financial Results and Business Update - The Manila Times
Skye Bioscience2026 Funding Rounds & List of Investors - Tracxn
Skye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026 - Quiver Quantitative
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update - GlobeNewswire
Press Release: UPDATE -- Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update - Moomoo
Skye Bioscience stock price target cut to $6 by Piper Sandler on cash runway - Investing.com
SKYE Advances CBeyond Program toward Phase 2b Trials - GuruFocus
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update - The Manila Times
SKYE: Promising Phase 2a combo results, but Q1 net loss and funding risks threaten future operations - TradingView
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Skye Bioscience, Inc. Quarterly Earnings Report - Stock Titan
Number of shareholders of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView
Skye weight-loss trial combo hits 22% mean loss at 52 weeks - Stock Titan
Biotech Overhyping Obesity Drug Hurt Investors, Suit Says - Law360
Skye Bioscience Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
SKYE Technical Analysis | Trend, Signals & Chart Patterns | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience (SKYE) CFO John P. Sharp files initial Form 3 - Stock Titan
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
1.27%
1.43%
자본화:
|
볼륨(24시간):